ANI Pharmaceuticals reported $637.11M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
ANI Pharmaceuticals USD 637.11M 39.9M Sep/2026
Aurora Cannabis CAD 76.28M 28.24M Jun/2026
Canopy Growth CAD 98.74M 23K Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 13.19B 3.9B Sep/2026
Omeros USD 59.16M 20.13M Jun/2024
Perrigo USD 961.4M 670.9M Sep/2026
Sun Pharmaceuticals INR 122.92B 5.49B Sep/2026
Teva Pharmaceutical Industries USD 3.18B 733M Sep/2026